ResearchGate, the professional network for researchers, and BMJ, a global leader in healthcare knowledge provision and a pioneer in open access (OA), have announced an agreement to make six BMJ OA journals available on the ResearchGate platform. This collaboration will provide wider reach and visibility to researchers, starting January 2024, and enhance accessibility to valuable healthcare knowledge.
The agreement covers a diverse set of BMJ’s OA journals highly pertinent to medical researchers: BMJ Global Health; BMJ Medicine; BMJ Neurology Open; BMJ Open Diabetes Research & Care; BMJ Open Opthalmology; and the Journal for ImmunoTherapy of Cancer. All version-of-record content from these six journals, including newly published articles and archive material, will be made available to ResearchGate’s highly relevant community of more than 25 million researchers globally.
Additionally, Journal Home will provide an enhanced online presence for the participating journals, with dedicated profiles for each journal and prominent journal visibility across all associated articles and touchpoints on ResearchGate. Potential authors will find a central location for each journal where they can learn more, discover relevant article content, and understand how, through their network, they are connected to the journal's community of authors and editors.
Authors publishing in these BMJ journals will enjoy the added advantage of their articles seamlessly integrated into their ResearchGate profiles, granting access to comprehensive statistics illustrating the impact of their work, such as readership and citations. This feature offers a distinctive opportunity for authors to engage and connect with their audience directly, fostering meaningful connections within the research community.
BMJ’s content can reach the research community on ResearchGate directly, amplifying accessibility of key medical research and fostering greater engagement among researchers. The development is in line with the open access trend and expands content visibility to a new global audience.
Click here to read the original press release.
